< -5%

-5% to -3%

ACGL

-3% to 0%

0% to 3%

3% to 5%

Intermittent fasting and OMAD diets remained popular for weight loss in 2025, DASH and anti-processed food diets rise for heart health and mindful eating, High-protein diets were favored for muscle building and satiety

* Intermittent fasting and OMAD diets remained popular for weight loss in 2025
* DASH and anti-processed food diets rise for heart health and mindful eating
* High-protein diets were favored for muscle building and satiety

Top 2025 diet trends include intermittent fasting, OMAD, DASH, high-protein diets, and anti-processed food diets. These focus on weight loss, improved metabolism, heart health, and mindful eating, but may not suit everyone and require medical advice.

shorts/health-and-fitness/from-omad-to-dash-these-were-the-5-most-popular-diets-of-2025

Sun Pharmaceutical Industries Ltd, the country’s largest drugmaker by revenue and market value, has slipped behind the Sensex and Nifty in 2025 — its first spell of underperformance in six years. The weakness reflects softer momentum in the US business, rising competition in generics, sustained pricing pressure at home and abroad, unfavorable currency movements across several emerging markets and continuing tariff uncertainty.

So far this year, the stock has declined about 8 percent even as both benchmark indices have risen close to 9 percent, Bloomberg data show. The broader pharma pack has also seen volatility, with Piramal Pharma down 35 percent, Mankind Pharma lower by 25 percent, Ipca Labs falling 15 percent, Lupin 11 percent, Aurobindo Pharma 8 percent and Dr Reddy’s Laboratories down 7 percent, while the Nifty Pharma index slipped 3.5 percent.

<img class="alignnone size-full wp-image-13747941" src="https://images.moneycontrol.com/static-mcnews/2025/12/20251230022255_sun-pharma.jpg" alt="sun pharma" width="700" height="700" />

US formulations delivered modest growth as competition intensified and gRevlimid volumes stayed subdued, limiting overall progress despite gains from innovative products. Analysts expect gRevlimid to make only a minimal contribution ahead, while higher research and development spending, elevated operating costs, slower revenue growth and a heavier tax burden continue to weigh on performance.

Regulatory scrutiny remains a headwind for the generics portfolio. Plants at Halol, Mohali, Dadra and Baska are at different stages of review and are implementing Corrective and Preventive Action plans. Recently, the USFDA has classified the Baska site as “Official Action Indicated,” without disclosing the number or nature of observations.

The facility manufactures key generic products including the Albuterol Ipratropium inhalant, which generates more than $100 million annually, and Amphotericin B, with sales of about $15 million. These products contribute an estimated seven percent of US revenue excluding gRevlimid and nearly two percent of core revenue, underscoring Baska’s role in Sun Pharma’s sterile-injectables network.

For now, generics remain outside tariff coverage and the proposed 100 percent tariffs on imported innovator medicines have not yet been implemented. The company does not face incremental import duties and, with part of its manufacturing base located in the US, is positioned to reassess plans if policy changes, analysts noted.

In the domestic market, performance has been steady despite pricing pressure, with momentum expected to build through recent launches such as Cequa for dry-eye disease, Tyvalzi for ischemic stroke, Rytstat for anaemia tied to chronic kidney disease and Lyvelsa to help reduce the risk of kidney failure linked to Type-2 diabetes. Analysts expect Sun Pharma to continue gaining share in the India Pharma Market, supported by strong therapy presence and an expanded field force.

Several analysts view the recent correction in large-cap pharma stocks as a buying opportunity, arguing that earnings visibility remains intact. Sun Pharma’s one-year forward price-earnings multiple stands at 32.15 times versus its 10-year average of 28 times. The stock trades at a premium to peers such as Lupin at 21.5 times, Dr Reddy’s at 20.26 times and Cipla at 25 times. According to Bloomberg, 37 of 43 analysts have a buy rating on the stock.

Brokerage Nirmal Bang has marginally pared estimates, citing firm operating costs, ongoing investment in research and development, softer topline trends and a rising tax burden. Its research highlights longer-term supports including sustained strength in branded formulations in India, the ramp-up of specialty products in the US such as LEQSELVI and UNLOXCYT, opportunities in dermatology, ophthalmology and onco-derma, and margins supported by disciplined execution.

Ownership, Material Conflicts of Interest and Disciplinary History

MCD is a wholly owned subsidiary of Network 18 Media & Investments Ltd ("Network18"), in which Independent Media Trust (IMT) holds 56.89% stake. Reliance Industries Limited ("RIL") is the sole beneficiary of IMT. Network18 and RIL and their subsidiaries, joint ventures and associates can be considered as associates of MCD.

Details of Associate

Receipt of Compensation

Third-Party Compensation

Employment History

Market-Making Activities

Use of Artificial Intelligence

Sun Pharma trails Sensex, Nifty first time in six years

Sun Pharmaceutical Industries Ltd, the country’s largest drugmaker by revenue and market value, has slipped behind the Sensex and Nifty in 2025 — its first spell of underperformance in six years. The weakness reflects softer momentum in the US business, rising competition in generics, sustained pricing pressure at home and abroad, unfavorable currency movements across several emerging markets and continuing tariff uncertainty.

So far this year, the stock has declined about 8 percent even as both benchmark indices have risen close to 9 percent, Bloomberg data show. The broader pharma pack has also seen volatility, with Piramal Pharma down 35 percent, Mankind Pharma lower by 25 percent, Ipca Labs falling 15 percent, Lupin 11 percent, Aurobindo Pharma 8 percent and Dr Reddy’s Laboratories down 7 percent, while the Nifty Pharma index slipped 3.5 percent.



US formulations delivered modest growth as competition intensified and gRevlimid volumes stayed subdued, limiting overall progress despite gains from innovative products. Analysts expect gRevlimid to make only a minimal contribution ahead, while higher research and development spending, elevated operating costs, slower revenue growth and a heavier tax burden continue to weigh on performance.

Regulatory scrutiny remains a headwind for the generics portfolio. Plants at Halol, Mohali, Dadra and Baska are at different stages of review and are implementing Corrective and Preventive Action plans. Recently, the USFDA has classified the Baska site as “Official Action Indicated,” without disclosing the number or nature of observations.

The facility manufactures key generic products including the Albuterol Ipratropium inhalant, which generates more than $100 million annually, and Amphotericin B, with sales of about $15 million. These products contribute an estimated seven percent of US revenue excluding gRevlimid and nearly two percent of core revenue, underscoring Baska’s role in Sun Pharma’s sterile-injectables network.

For now, generics remain outside tariff coverage and the proposed 100 percent tariffs on imported innovator medicines have not yet been implemented. The company does not face incremental import duties and, with part of its manufacturing base located in the US, is positioned to reassess plans if policy changes, analysts noted.

In the domestic market, performance has been steady despite pricing pressure, with momentum expected to build through recent launches such as Cequa for dry-eye disease, Tyvalzi for ischemic stroke, Rytstat for anaemia tied to chronic kidney disease and Lyvelsa to help reduce the risk of kidney failure linked to Type-2 diabetes. Analysts expect Sun Pharma to continue gaining share in the India Pharma Market, supported by strong therapy presence and an expanded field force.

Several analysts view the recent correction in large-cap pharma stocks as a buying opportunity, arguing that earnings visibility remains intact. Sun Pharma’s one-year forward price-earnings multiple stands at 32.15 times versus its 10-year average of 28 times. The stock trades at a premium to peers such as Lupin at 21.5 times, Dr Reddy’s at 20.26 times and Cipla at 25 times. According to Bloomberg, 37 of 43 analysts have a buy rating on the stock.

Brokerage Nirmal Bang has marginally pared estimates, citing firm operating costs, ongoing investment in research and development, softer topline trends and a rising tax burden. Its research highlights longer-term supports including sustained strength in branded formulations in India, the ramp-up of specialty products in the US such as LEQSELVI and UNLOXCYT, opportunities in dermatology, ophthalmology and onco-derma, and margins supported by disciplined execution.

Bitcoin reached record highs in 2025 after US regulations and Trump's support., India leads global crypto adoption for third year, with rising institutional investments., Stablecoins processed $46T in transfers in 2025, gaining payment traction.

* Bitcoin reached record highs in 2025 after US regulations and Trump's support.
* India leads global crypto adoption for third year, with rising institutional investments.
* Stablecoins processed $46T in transfers in 2025, gaining payment traction.

In 2025, US regulatory clarity and Trump’s crypto support drove Bitcoin to record highs before a market correction. India led global crypto adoption, with rising institutional investment and SIPs, while stablecoins and AI-blockchain integration gained traction.

shorts/business/trump-era-regulations-bitcoin-s-record-run-institutional-inflows-mark-crypto-s-inflection-point-in-2025

<a href="https://www.moneycontrol.com/india/stockpricequote/aerospacedefence/bharatelectronics/BE03">Bharat Electronics</a> (BEL) share price will remain in focus on December 30 following the company secured additional orders worth Rs 569 crore since last disclosure on December 12, 2025.

The major orders received include radars, tank overhaul, communication equipment, fire control systems, simulators, antenna stabilization systems, security software, components, upgrades, spares, services etc.

<a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-updates-gift-nifty-indicates-a-flat-start-us-asian-markets-fall-3-liveblog-13747857.html">Catch all the market action on our live blog</a>

On December 12, the company bagged orders worth Rs 776 crore including indigenous Counter Unmanned Aerial System (SAKSHAM), software defined Radios, anti drone systems, communication equipment, medical electronics, gun control systems, weapon control systems, security software, avionics, masts, components, upgrades, spares, services etc.

In the month of November, the company secured additional orders worth Rs 871 crore including fire control system, thermal imager, ground support equipment, upgrades, spares, services etc and secured additional orders worth Rs 792 crore including defence network upgrade, radio communication network, radars, communication equipment, drones, combat management system, gun sighting system, upgrades, spares, services etc.

In the previous trading session, the share closed at Rs 393.40, down Rs 5, or 1.26 percent.

The share touched a 52-week high of Rs 435.95 and a 52-week low of Rs 240.15 on 01 July, 2025 and 19 February, 2025, respectively.

Currently, the stock is trading 9.76 percent below its 52-week high and 63.81 percent above its 52-week low.

The market capitalisation of the company stands at Rs 287,566.70 crore.

Bharat Electronics shares in focus on orders win worth Rs 569 crore

Bharat Electronics (BEL) share price will remain in focus on December 30 following the company secured additional orders worth Rs 569 crore since last disclosure on December 12, 2025.

The major orders received include radars, tank overhaul, communication equipment, fire control systems, simulators, antenna stabilization systems, security software, components, upgrades, spares, services etc.

Catch all the market action on our live blog

On December 12, the company bagged orders worth Rs 776 crore including indigenous Counter Unmanned Aerial System (SAKSHAM), software defined Radios, anti drone systems, communication equipment, medical electronics, gun control systems, weapon control systems, security software, avionics, masts, components, upgrades, spares, services etc.

In the month of November, the company secured additional orders worth Rs 871 crore including fire control system, thermal imager, ground support equipment, upgrades, spares, services etc and secured additional orders worth Rs 792 crore including defence network upgrade, radio communication network, radars, communication equipment, drones, combat management system, gun sighting system, upgrades, spares, services etc.

In the previous trading session, the share closed at Rs 393.40, down Rs 5, or 1.26 percent.

The share touched a 52-week high of Rs 435.95 and a 52-week low of Rs 240.15 on 01 July, 2025 and 19 February, 2025, respectively.

Currently, the stock is trading 9.76 percent below its 52-week high and 63.81 percent above its 52-week low.

The market capitalisation of the company stands at Rs 287,566.70 crore.

<a href="https://www.moneycontrol.com/india/stockpricequote/miscellaneous/cupid/CR02">Cupid</a> share price will remain in focus on December 30 following board approval for setting up manufacturing facility in Saudi Arabia.

".... the board of directors of the company at its meeting held on December 29, has accorded in-principle approval for setting up a new FMCG manufacturing facility / plant in the Kingdom of Saudi Arabia (KSA)," company said in its exchange filing.

The proposed facility is intended to support Cupid Limited's FMCG expansion strategy and is expected to enhance regional supply capabilities, improve speed-to market and product availability, and strengthen the Company's market penetration in KSA and the wider GCC region, company said.

The project is proposed to be funded through the Company's internal accruals, and will be progressed subject to customary evaluations and necessary regulatory / statutory approvals, it added further.

<a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-updates-gift-nifty-indicates-a-flat-start-us-asian-markets-fall-3-liveblog-13747857.html">Catch all the market action on our live blog</a>

In an exchange filing released on December 23, Cupid announced that the pledged shareholding in the company stands at 20 percent, after being reduced from 36.13 percent as on September 30.

The company had reported 140 percent jump in its Q2FY26 net profit at Rs 24.12 crore against Rs 10.04 crore, YoY.

The company manufactures and supplies male and female condoms, water-based lubricant jelly and IVD kits. The company has a current capacity of over 480 million pieces for male condoms, 52 million pieces of the female condoms and 210 million sachets of lubricant jelly per annum.

In the previous trading session, the share closed at Rs 486.50, up Rs 7.20, or 1.50 percent.

The share touched a 52-week high of Rs 493.15 and a 52-week low of Rs 50.00 on 29 December, 2025 and 07 April, 2025, respectively.

Currently, the stock is trading 1.35 percent below its 52-week high and 873 percent above its 52-week low.

The market capitalisation of the company stands at Rs 13,055.47 crore.

Cupid share price in focus on setting up manufacturing facility in Saudi Arabia

Cupid share price will remain in focus on December 30 following board approval for setting up manufacturing facility in Saudi Arabia.

&quot;.... the board of directors of the company at its meeting held on December 29, has accorded in-principle approval for setting up a new FMCG manufacturing facility / plant in the Kingdom of Saudi Arabia (KSA),&quot; company said in its exchange filing.

The proposed facility is intended to support Cupid Limited's FMCG expansion strategy and is expected to enhance regional supply capabilities, improve speed-to market and product availability, and strengthen the Company's market penetration in KSA and the wider GCC region, company said.

The project is proposed to be funded through the Company's internal accruals, and will be progressed subject to customary evaluations and necessary regulatory / statutory approvals, it added further.

Catch all the market action on our live blog

In an exchange filing released on December 23, Cupid announced that the pledged shareholding in the company stands at 20 percent, after being reduced from 36.13 percent as on September 30.

The company had reported 140 percent jump in its Q2FY26 net profit at Rs 24.12 crore against Rs 10.04 crore, YoY.

The company manufactures and supplies male and female condoms, water-based lubricant jelly and IVD kits. The company has a current capacity of over 480 million pieces for male condoms, 52 million pieces of the female condoms and 210 million sachets of lubricant jelly per annum.

In the previous trading session, the share closed at Rs 486.50, up Rs 7.20, or 1.50 percent.

The share touched a 52-week high of Rs 493.15 and a 52-week low of Rs 50.00 on 29 December, 2025 and 07 April, 2025, respectively.

Currently, the stock is trading 1.35 percent below its 52-week high and 873 percent above its 52-week low.

The market capitalisation of the company stands at Rs 13,055.47 crore.

Stocks like Lupin, Rail Vikas Nigam, Bharat Electronics, Indian Overseas Bank, Waaree Energies, Afcons Infrastructure, Nazara Technologies, Entero Healthcare Solutions, Honasa Consumer, Mangalam Drugs and Organics, Gujarat Kidney & Super Speciality, and Shyam Dhani Industries will be in focus on December 30.

Delhi’s IGI Airport operated under CAT III conditions due to dense fog, causing flight delays. CAT III allows landings with minimal visibility using instrument guidance, but not all aircraft, crews, or runways are certified, leading to ongoing disruptions.

shorts/business/stocks-to-watch-today-lupin-rail-vikas-nigam-bel-gujarat-kidney-shyam-dhani-cupid-waaree-energies-indian-overseas-bank-in-focus-on-30-december

Let's catch up on the latest news from the stock market. From significant investments to major deals, order wins, and acquisitions, here’s a quick look at which stocks will be in focus in today's trade:

Stocks to Watch

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/lupin/L">Lupin</a>

The pharma company has entered into an exclusive License, Supply, and Distribution Agreement with Gan &amp; Lee Pharmaceuticals, headquartered in China, for a novel fortnightly GLP-1 receptor agonist, Bofanglutide.

Bofanglutide injection is used for the treatment of type 2 diabetes and for aiding weight management in overweight or obese individuals.

<a href="https://www.moneycontrol.com/india/stockpricequote/miscellaneous/railvikasnigam/RVN">Rail Vikas Nigam</a>

The company has emerged as the lowest bidder for an order worth Rs 201.23 crore from East Coast Railway. The order involves setting up a wagon POH workshop with a capacity of 200 wagons at Kantabanji.

<a href="https://www.moneycontrol.com/india/stockpricequote/aerospacedefence/bharatelectronics/BE03">Bharat Electronics</a>

The company has received additional orders worth Rs 569 crore since December 12. These include orders for radars, tank overhauls, communication equipment, fire control systems, simulators, antenna stabilization systems, security software, components, upgrades, and spares.

<a href="https://www.moneycontrol.com/india/stockpricequote/banks-public-sector/indianoverseasbank/IOB">Indian Overseas Bank</a>

The Reserve Bank of India has permitted Indian Overseas Bank to set up an IFSC Banking Unit (IBU) in GIFT City, Gujarat.

<a href="https://www.moneycontrol.com/india/stockpricequote/electric-equipment/waareeenergies/WEL01">Waaree Energies</a>

Amit Paithankar has resigned from the position of Whole-Time Director and Chief Executive Officer of the company to pursue opportunities outside the organization, effective May 15, 2026.

However, the Board has approved the appointment of Jignesh Rathod (currently designated as Director – Operations) as Chief Executive Officer-Designate with immediate effect. Further, the Board has appointed Jignesh Rathod as Chief Executive Officer and Key Managerial Personnel of the company, effective May 16, 2026.

Additionally, the company’s subsidiary, Waaree Power, has set up two solar inverter line manufacturing facilities, each with an annual capacity of 1.525 GW, totaling 3.05 GW, at its factory in Sarodhi-Valsad, Gujarat. Operations at the facility commenced on December 29.

<a href="https://www.moneycontrol.com/india/stockpricequote/fertilizers/gujaratnarmadavalleyfertchem/GNV">Gujarat Narmada Valley Fertilizers &amp; Chemicals</a>

T Natarajan has resigned as Managing Director of the company, effective December 29, following an order from the Government of Gujarat.

The Government of Gujarat has nominated Rajkumar Beniwal, IAS, as Managing Director of the company, effective December 29.

<a href="https://www.moneycontrol.com/india/stockpricequote/steel-mediumsmall/lloydsengineeringworks/LSI02">Lloyds Engineering Works</a>

The Board has approved the merger of Lloyds Infrastructure &amp; Construction, Metalfab Hightech, and Techno Industries with Lloyds Engineering Works.

<a href="https://www.moneycontrol.com/india/stockpricequote/diversified/grasimindustries/GI01">Grasim Industries</a>

The Board has approved a Composite Scheme of Arrangement among Aditya Birla Renewables, Essel Mining &amp; Industries, Electrotherm Renewables, ABREL EPCCO Services, ABREL Renewables EPC, ABREL EPC, and their respective shareholders and creditors.

<a href="https://www.moneycontrol.com/india/stockpricequote/lubricants/gulfoillubricantsindia/GOL01">Gulf Oil Lubricants India</a>

The company has launched its new range of Gulf Syntrac, a 100% fully synthetic premium motorcycle engine oil range.

<a href="https://www.moneycontrol.com/india/stockpricequote/miscellaneous/timexgroupindia/TGI">Timex Group India</a>

Promoter Timex Group Luxury Watches B.V., Netherlands, has decided to exercise the oversubscription option to the extent of 45.09 lakh equity shares (4.47% stake) in the offer-for-sale on December 30, in addition to the base offer size of a 4.47% stake.

<a href="https://www.moneycontrol.com/india/stockpricequote/infrastructure/afconsinfrastructure/AIL08">Afcons Infrastructure</a>

The company has achieved the first tunnel breakthrough in the City and Industrial Development Corporation’s (CIDCO) augmentation of the Hetawane Water Supply Scheme at Shaft-4 in Wahal village, Navi Mumbai.

The company stated that it would complete the project six months ahead of schedule. CIDCO has undertaken this project to meet the growing water demand in Navi Mumbai’s developing regions.

<a href="https://www.moneycontrol.com/india/stockpricequote/miscellaneous/cupid/CR02">Cupid</a>

The company has received in-principle approval from its Board of Directors to set up a new FMCG manufacturing facility in the Kingdom of Saudi Arabia (KSA).

This will be the company’s first manufacturing plant outside India, supporting its FMCG growth strategy and strengthening its presence in overseas markets, beginning with the Gulf Cooperation Council (GCC) region.

<a href="https://www.moneycontrol.com/india/stockpricequote/power-generationdistribution/ntpcgreenenergy/NGE">NTPC Green Energy</a>

The company has announced the commencement of commercial operations of the ninth part capacity of 13.98 MW out of the 1,255 MW Khavda-I Solar PV project of NTPC Renewable Energy.

The current commercial capacity of NTPC Green Energy stands at 7,996.30 MW. With the addition of this capacity, the total installed capacity of the NGEL Group will increase to 8,010.28 MW.

Bulk Deals

<a href="https://www.moneycontrol.com/india/stockpricequote/software/nazaratechnologies/NT">Nazara Technologies</a>

SBI Mutual Fund sold 45.09 lakh shares in Nazara Technologies at Rs 240.18 per share and another 45 lakh shares at Rs 240.03 per share, totaling a 2.4% stake and amounting to over Rs 216 crore.

SBI Mutual Fund held a 5.78% stake in Nazara Technologies as of September 2025.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticalsdrugs/enterohealthcaresolutions/EHSL">Entero Healthcare Solutions</a>

Capital Group-owned Smallcap World Fund Inc sold 22.69 lakh shares (equivalent to 5.2% of paid-up equity) in Entero at Rs 950 per share for Rs 215.6 crore. Meanwhile, ICICI Prudential Mutual Fund acquired 21.82 lakh shares (5.01% stake) at the same price for Rs 207.29 crore.

Smallcap World Fund held a 5.42% stake in Entero as of September 2025.

<a href="https://www.moneycontrol.com/india/stockpricequote/householdpersonal-products/honasaconsumer/HCL06">Honasa Consumer</a>

Promoter Varun Alagh has bought an additional 18.51 lakh shares (0.56% stake) in the company at Rs 270 per share for nearly Rs 50 crore from Fireside Ventures Investment Fund I.

Fireside Ventures Investment Fund held a 1.93% stake in the parent company of Mamaearth as of September 2025.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/mangalamdrugsorganics/MDO">Mangalam Drugs and Organics</a>

Kedia Securities, owned by ace investor Vijay Kedia, picked up 1.37 lakh shares (0.87% stake) in the pharma company at Rs 24.15 per share for Rs 33.27 lakh.

<a href="https://www.moneycontrol.com/india/stockpricequote/cement-productsbuilding-materials/birlanu/HI09">BirlaNu</a>

Promoter Birla Chandrakant has acquired 29.28 lakh shares (38.83% stake) in BirlaNu at Rs 1,517.5 per share for Rs 444.3 crore from Shekhavati Investments and Traders, Gwalior Finance Corporation, Central India Industries, Ashok Investment Corporation, and Amer Investments Delhi, all of which are part of the promoter group.

Further, Birla Chandrakant has bought 79,666 shares in BirlaNu at Rs 1,569.36 per share for Rs 12.5 crore. Meanwhile, Hitaishi Investments sold 67,066 shares at Rs 1,575.64 per share for Rs 10.56 crore.

Mainboard Listing

Gujarat Kidney &amp; Super Speciality

SME Listing

Shyam Dhani Industries
Sundrex Oil Company
Dachepalli Publishers
EPW India

Stock in F&amp;O ban

Sammaan Capital

Stocks to Watch Today: Lupin, Rail Vikas Nigam, BEL, Gujarat Kidney, Shyam Dhani, Cupid, Waaree Energies, Indian Overseas Bank in focus on 30 December

Let's catch up on the latest news from the stock market. From significant investments to major deals, order wins, and acquisitions, here’s a quick look at which stocks will be in focus in today's trade:

Stocks to Watch

Lupin

The pharma company has entered into an exclusive License, Supply, and Distribution Agreement with Gan &amp;amp; Lee Pharmaceuticals, headquartered in China, for a novel fortnightly GLP-1 receptor agonist, Bofanglutide.

Bofanglutide injection is used for the treatment of type 2 diabetes and for aiding weight management in overweight or obese individuals.

Rail Vikas Nigam

The company has emerged as the lowest bidder for an order worth Rs 201.23 crore from East Coast Railway. The order involves setting up a wagon POH workshop with a capacity of 200 wagons at Kantabanji.

Bharat Electronics

The company has received additional orders worth Rs 569 crore since December 12. These include orders for radars, tank overhauls, communication equipment, fire control systems, simulators, antenna stabilization systems, security software, components, upgrades, and spares.

Indian Overseas Bank

The Reserve Bank of India has permitted Indian Overseas Bank to set up an IFSC Banking Unit (IBU) in GIFT City, Gujarat.

Waaree Energies

Amit Paithankar has resigned from the position of Whole-Time Director and Chief Executive Officer of the company to pursue opportunities outside the organization, effective May 15, 2026.

However, the Board has approved the appointment of Jignesh Rathod (currently designated as Director – Operations) as Chief Executive Officer-Designate with immediate effect. Further, the Board has appointed Jignesh Rathod as Chief Executive Officer and Key Managerial Personnel of the company, effective May 16, 2026.

Additionally, the company’s subsidiary, Waaree Power, has set up two solar inverter line manufacturing facilities, each with an annual capacity of 1.525 GW, totaling 3.05 GW, at its factory in Sarodhi-Valsad, Gujarat. Operations at the facility commenced on December 29.

Gujarat Narmada Valley Fertilizers &amp;amp; Chemicals

T Natarajan has resigned as Managing Director of the company, effective December 29, following an order from the Government of Gujarat.

The Government of Gujarat has nominated Rajkumar Beniwal, IAS, as Managing Director of the company, effective December 29.

Lloyds Engineering Works

The Board has approved the merger of Lloyds Infrastructure &amp;amp; Construction, Metalfab Hightech, and Techno Industries with Lloyds Engineering Works.

Grasim Industries

The Board has approved a Composite Scheme of Arrangement among Aditya Birla Renewables, Essel Mining &amp;amp; Industries, Electrotherm Renewables, ABREL EPCCO Services, ABREL Renewables EPC, ABREL EPC, and their respective shareholders and creditors.

Gulf Oil Lubricants India

The company has launched its new range of Gulf Syntrac, a 100% fully synthetic premium motorcycle engine oil range.

Timex Group India

Promoter Timex Group Luxury Watches B.V., Netherlands, has decided to exercise the oversubscription option to the extent of 45.09 lakh equity shares (4.47% stake) in the offer-for-sale on December 30, in addition to the base offer size of a 4.47% stake.

Afcons Infrastructure

The company has achieved the first tunnel breakthrough in the City and Industrial Development Corporation’s (CIDCO) augmentation of the Hetawane Water Supply Scheme at Shaft-4 in Wahal village, Navi Mumbai.

The company stated that it would complete the project six months ahead of schedule. CIDCO has undertaken this project to meet the growing water demand in Navi Mumbai’s developing regions.

Cupid

The company has received in-principle approval from its Board of Directors to set up a new FMCG manufacturing facility in the Kingdom of Saudi Arabia (KSA).

This will be the company’s first manufacturing plant outside India, supporting its FMCG growth strategy and strengthening its presence in overseas markets, beginning with the Gulf Cooperation Council (GCC) region.

NTPC Green Energy

The company has announced the commencement of commercial operations of the ninth part capacity of 13.98 MW out of the 1,255 MW Khavda-I Solar PV project of NTPC Renewable Energy.

The current commercial capacity of NTPC Green Energy stands at 7,996.30 MW. With the addition of this capacity, the total installed capacity of the NGEL Group will increase to 8,010.28 MW.

Bulk Deals

Nazara Technologies

SBI Mutual Fund sold 45.09 lakh shares in Nazara Technologies at Rs 240.18 per share and another 45 lakh shares at Rs 240.03 per share, totaling a 2.4% stake and amounting to over Rs 216 crore.

SBI Mutual Fund held a 5.78% stake in Nazara Technologies as of September 2025.

Entero Healthcare Solutions

Capital Group-owned Smallcap World Fund Inc sold 22.69 lakh shares (equivalent to 5.2% of paid-up equity) in Entero at Rs 950 per share for Rs 215.6 crore. Meanwhile, ICICI Prudential Mutual Fund acquired 21.82 lakh shares (5.01% stake) at the same price for Rs 207.29 crore.

Smallcap World Fund held a 5.42% stake in Entero as of September 2025.

Honasa Consumer

Promoter Varun Alagh has bought an additional 18.51 lakh shares (0.56% stake) in the company at Rs 270 per share for nearly Rs 50 crore from Fireside Ventures Investment Fund I.

Fireside Ventures Investment Fund held a 1.93% stake in the parent company of Mamaearth as of September 2025.

Mangalam Drugs and Organics

Kedia Securities, owned by ace investor Vijay Kedia, picked up 1.37 lakh shares (0.87% stake) in the pharma company at Rs 24.15 per share for Rs 33.27 lakh.

BirlaNu

Promoter Birla Chandrakant has acquired 29.28 lakh shares (38.83% stake) in BirlaNu at Rs 1,517.5 per share for Rs 444.3 crore from Shekhavati Investments and Traders, Gwalior Finance Corporation, Central India Industries, Ashok Investment Corporation, and Amer Investments Delhi, all of which are part of the promoter group.

Further, Birla Chandrakant has bought 79,666 shares in BirlaNu at Rs 1,569.36 per share for Rs 12.5 crore. Meanwhile, Hitaishi Investments sold 67,066 shares at Rs 1,575.64 per share for Rs 10.56 crore.

Mainboard Listing

Gujarat Kidney &amp;amp; Super Speciality

SME Listing

Shyam Dhani Industries
Sundrex Oil Company
Dachepalli Publishers
EPW India

Stock in F&amp;amp;O ban

Sammaan Capital

Smallcap World Fund was holding 5.42 percent stake in Entero as of September 2025.

Four people died and nine were injured in Mumbai after a bus accident near Bhandup railway station, where sidewalk encroachment by hawkers forced pedestrians onto the road. Police are investigating all factors, including the bus driver’s condition.

shorts/business/sbi-mf-sells-2-4-in-nazara-for-rs-216-crore-smallcap-world-exits-5-2-of-entero

SBI Mutual Fund has offloaded 2.4 percent equity stake in Nazara Technologies, the gaming and sports media platform, via open market transactions on December 29, while promoter has acquired Rs 50 crore worth shares in Honasa Consumer, the digital-first beauty and personal care company.

Despite big stake sale, <a href="https://www.moneycontrol.com/india/stockpricequote/software/nazaratechnologies/NT">Nazara Technologies</a> shares rallied 6.7 percent to close at Rs 253.3 on the NSE, especially after the past couple of days of consolidation.

As per the bulk deals data published by exchanges, SBI Mutual Fund sold 45.09 lakh shares in Nazara at Rs 240.18 per share, and 45 lakh shares at Rs 240.03 per share, which total amounted to over Rs 216 crore.

SBI Mutual Fund held 5.78 percent stake in Nazara Technologies as of September 2025.

The major action was also seen in <a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticalsdrugs/enterohealthcaresolutions/EHSL">Entero Healthcare Solutions</a> which shares ended at new closing low of Rs 949.20, down 0.35 percent.

Capital Group-owned Smallcap World Fund Inc sold 22.69 lakh shares (equivalent to 5.2 percent of paid-up equity) in Entero, the healthcare products distribution platform, at Rs 950 per share for Rs 215.6 crore. However, ICICI Prudential Mutual Fund has acquired 21.82 lakh shares (5.01 percent stake) at same price for Rs 207.29 crore.

Smallcap World Fund was holding 5.42 percent stake in Entero as of September 2025.

<a href="https://www.moneycontrol.com/india/stockpricequote/householdpersonal-products/honasaconsumer/HCL06">Honasa Consumer</a> has also seen exchange of shares on Monday, which rallied 3.18 percent to Rs 277. Promoter Varun Alagh has bought additional 18.51 lakh shares (0.56 percent) stake) in the company at Rs 270 per share for nearly Rs 50 crore, from Fireside Ventures Investment Fund I.

Fireside Ventures Investment Fund held 1.93 percent stake in the parent company of Mamaearth, as of September 2025.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/mangalamdrugsorganics/MDO">Mangalam Drugs and Organics</a> was locked in 5 percent upper circuit at Rs 24.96, perhaps may be after Kedia Securities, owned by ace investor Vijay Kedia, picked up 1.37 lakh shares (0.87 percent stake) in the pharma company at Rs 24.15 per share for Rs 33.27 lakh.

The major action was also seen in <a href="https://www.moneycontrol.com/india/stockpricequote/cement-productsbuilding-materials/birlanu/HI09">BirlaNu</a> (earlier known as HIL), the building materials company of CK Birla Group, as its shares surged 11.71 percent to Rs 1,695.20 amid high volumes after the big internal share transfer between promoter and promoter entities.

Promoter Birla Chandrakant has acquired 29.28 lakh shares (38.83 percent stake) in BirlaNu at Rs 1,517.5 per share for Rs 444.3 crore, from Shekhavati Investments and Traders, Gwalior Finance Corporation, Central India Industries, Ashok Investment Corporation, and Amer Investments Delhi which all are part of promoter group.

Further, Birla Chandrakant has bought 79,666 shares in BirlaNu at Rs 1,569.36 per share for Rs 12.5 crore, however, Hitaishi Investments sold 67,066 shares at Rs 1,575.64 per share for Rs 10.56 crore.

<img class="alignnone size-full wp-image-13747800 aligncenter" src="https://images.moneycontrol.com/static-mcnews/2025/12/20251229203140_Image2129122025.jpg" alt="Image2129122025" width="700" height="1602" />

SBI MF sells 2.4% in Nazara for Rs 216 crore; Smallcap World exits 5.2% of Entero

SBI Mutual Fund has offloaded 2.4 percent equity stake in Nazara Technologies, the gaming and sports media platform, via open market transactions on December 29, while promoter has acquired Rs 50 crore worth shares in Honasa Consumer, the digital-first beauty and personal care company.

Despite big stake sale, Nazara Technologies shares rallied 6.7 percent to close at Rs 253.3 on the NSE, especially after the past couple of days of consolidation.

As per the bulk deals data published by exchanges, SBI Mutual Fund sold 45.09 lakh shares in Nazara at Rs 240.18 per share, and 45 lakh shares at Rs 240.03 per share, which total amounted to over Rs 216 crore.

SBI Mutual Fund held 5.78 percent stake in Nazara Technologies as of September 2025.

The major action was also seen in Entero Healthcare Solutions which shares ended at new closing low of Rs 949.20, down 0.35 percent.

Capital Group-owned Smallcap World Fund Inc sold 22.69 lakh shares (equivalent to 5.2 percent of paid-up equity) in Entero, the healthcare products distribution platform, at Rs 950 per share for Rs 215.6 crore. However, ICICI Prudential Mutual Fund has acquired 21.82 lakh shares (5.01 percent stake) at same price for Rs 207.29 crore.

Smallcap World Fund was holding 5.42 percent stake in Entero as of September 2025.

Honasa Consumer has also seen exchange of shares on Monday, which rallied 3.18 percent to Rs 277. Promoter Varun Alagh has bought additional 18.51 lakh shares (0.56 percent) stake) in the company at Rs 270 per share for nearly Rs 50 crore, from Fireside Ventures Investment Fund I.

Fireside Ventures Investment Fund held 1.93 percent stake in the parent company of Mamaearth, as of September 2025.

Mangalam Drugs and Organics was locked in 5 percent upper circuit at Rs 24.96, perhaps may be after Kedia Securities, owned by ace investor Vijay Kedia, picked up 1.37 lakh shares (0.87 percent stake) in the pharma company at Rs 24.15 per share for Rs 33.27 lakh.

The major action was also seen in BirlaNu (earlier known as HIL), the building materials company of CK Birla Group, as its shares surged 11.71 percent to Rs 1,695.20 amid high volumes after the big internal share transfer between promoter and promoter entities.

Promoter Birla Chandrakant has acquired 29.28 lakh shares (38.83 percent stake) in BirlaNu at Rs 1,517.5 per share for Rs 444.3 crore, from Shekhavati Investments and Traders, Gwalior Finance Corporation, Central India Industries, Ashok Investment Corporation, and Amer Investments Delhi which all are part of promoter group.

Further, Birla Chandrakant has bought 79,666 shares in BirlaNu at Rs 1,569.36 per share for Rs 12.5 crore, however, Hitaishi Investments sold 67,066 shares at Rs 1,575.64 per share for Rs 10.56 crore.

Auto Ancillaries - Bus Body Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Auto Ancillaries - Bus Body industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q2 FY25-26

Stock News

Sun Pharma trails Sensex, Nifty first time in six years

Bharat Electronics shares in focus on orders win worth Rs 569 crore

Cupid share price in focus on setting up manufacturing facility in Saudi Arabia

Stocks to Watch Today: Lupin, Rail Vikas Nigam, BEL, Gujarat Kidney, Shyam Dhani, Cupid, Waaree Energies, Indian Overseas Bank in focus on 30 December

SBI MF sells 2.4% in Nazara for Rs 216 crore; Smallcap World exits 5.2% of Entero

Auto Ancillaries - Bus Body Industry StocksCheck latest stock performance, list of stocks, earnings review & more details about the Auto Ancillaries - Bus Body industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q2 FY25-26

Stock News

Sun Pharma trails Sensex, Nifty first time in six years

Bharat Electronics shares in focus on orders win worth Rs 569 crore

Cupid share price in focus on setting up manufacturing facility in Saudi Arabia

Stocks to Watch Today: Lupin, Rail Vikas Nigam, BEL, Gujarat Kidney, Shyam Dhani, Cupid, Waaree Energies, Indian Overseas Bank in focus on 30 December

SBI MF sells 2.4% in Nazara for Rs 216 crore; Smallcap World exits 5.2% of Entero

Auto Ancillaries - Bus Body Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Auto Ancillaries - Bus Body industry stocks.